Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Phase I controlled trials of WR-2721 and cyclophosphamide

Conference · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)
OSTI ID:6166463
; ; ; ; ;
WR-2721 is an organic thiophosphate compound which in the animal model selectively protects against the hematologic toxicity of cyclophosphamide by factors of 1.5 to 2.0. Controlled Phase I trials of WR-2721 and cyclophosphamide were initiated to determine if WR-2721 protected against cyclophosphamide's hematolgic toxicity. Fifteen patients received WR-2721 prior to cyclophosphamide and were subsequently retreated 4 weeks later with the same cyclophosphamide dose alone. With WR-2721 pretreatment, 11/15 (73%) patients had improved WBC counts. In the second trial, 25 patients received the reverse sequence: an initial dose of cyclophosphamide alone, followed 4 weeks later by WR-2721 prior to the same dose of cyclophosphamide. With WR-2721 pretreatment, 12/25 (48%) patients had improved nadir WBC counts. No patient developed microscopic or gross hematuria or inappropriate antidiuretic hormone secretion. These data suggest that WR-2721 provides significant protection against cyclophosphamide-induced granulocytopenia, but the dose modification factors and degree of clinical benefit remain to be established. The current recommended WR-2721 dose for Phase II trials is 740 mg/m/sup 2/ administered over 15 minutes.
Research Organization:
Univ. of Pennsylvania, Philadelphia
OSTI ID:
6166463
Report Number(s):
CONF-8311204-
Conference Information:
Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Journal Volume: 10:9
Country of Publication:
United States
Language:
English

Similar Records

Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide
Journal Article · Mon Feb 28 23:00:00 EST 1983 · J. Clin. Oncol.; (United States) · OSTI ID:6848718
WR-2721: enhanced chemoprotection by increasing cyclophosphamide activation with phenobarbitol
Journal Article · Sun Feb 28 23:00:00 EST 1982 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:6702372
Protection by WR-2721 of human bone marrow function following irradiation
Journal Article · Fri Aug 01 00:00:00 EDT 1986 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:7187543

Related Subjects

550603 -- Medicine-- External Radiation in Therapy-- (1980-)
560151* -- Radiation Effects on Animals-- Man
62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ALKYLATING AGENTS
BIOLOGICAL EFFECTS
BIOLOGICAL MATERIALS
BIOLOGICAL RADIATION EFFECTS
BLOOD
BLOOD CELLS
BLOOD COUNT
BODY FLUIDS
CHEMOTHERAPY
DRUGS
ENDOXAN
HEMATOLOGY
IMMUNOSUPPRESSIVE DRUGS
LEUKOCYTES
MATERIALS
MEDICINE
ORGANIC COMPOUNDS
ORGANIC SULFUR COMPOUNDS
PATIENTS
RADIATION EFFECTS
RADIOPROTECTIVE SUBSTANCES
THERAPY
THIOLS